nach oben

Erschienen in:

01.04.2008 | Original Article

How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett’s esophagus

verfasst von: Gary D. Mackenzie, Neil F. Jamieson, Marco R. Novelli, C. Alexander Mosse, Benjamin R. Clark, Sally M. Thorpe, Stephen G. Bown, Laurence B. Lovat

Erschienen in: Lasers in Medical Science | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) is a novel treatment for high-grade dysplasia (HGD) in Barrett’s esophagus (BE). Our aim was to evaluate the effectiveness of differing light doses. Patients with HGD in BE received oral ALA (60 mg/kg) activated by low (500 J/cm), medium (750 J/cm), high (1,000 J/cm), or highest (1,000 J/cm ×2) light dose at 635 nm. Follow-up was by regular endoscopy with quadrantic biopsies. Twenty-four patients were treated. Successful eradication of HGD was significantly correlated with light dose (log rank, p < 0.01). Six of eight patients (75%) treated with the highest light dose, one of two treated with high dose (50%), two of nine (22%) receiving medium light dose, and zero of five receiving low light dose had successful eradication of HGD (median follow-up 45 months, range 1–78 months). No skin photosensitivity or esophageal strictures occurred. The efficacy of ALA-PDT for eradication of HGD in BE is closely related to the light dose used. With a drug dose of 60 mg/kg and light at 635 nm, we recommend a minimum light dose of 1,000 J/cm of esophagus. This dose appears safe.

Hansen S, Wiig JN, Giercksky KE et al (1997) Esophageal and gastric carcinoma in Norway 1958–1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 71(3):340–344PubMedCrossRef

Cameron AJ, Ott BJ, Payne WS (1985) The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med 313(14):857–859PubMedCrossRef

Cameron AJ, Carpenter HA (1997) Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 92(4):586–591PubMed

Hirota WK, Loughney TM, Lazas DJ et al (1999) Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 116(2):277–285PubMedCrossRef

Montgomery E, Goldblum JR, Greenson JK et al (2001) Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32(4):379–388PubMedCrossRef

Reid BJ, Levine DS, Longton G et al (2000) Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95(7):1669–1676PubMed

Schnell TG, Sontag SJ, Chejfec G et al (2001) Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 120(7):1607–1619PubMedCrossRef

Heitmiller RF (2003) Prophylactic esophagectomy in Barrett esophagus with high-grade dysplasia. Langenbecks Arch Surg 388(2):83–87PubMed

Tseng EE, Wu TT, Yeo CJ et al (2003) Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome—an update. J Gastrointest Surg 7(2):164–170PubMedCrossRef

10.

Swisher SG, Deford L, Merriman KW et al (2000) Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 119(6):1126–1132PubMedCrossRef

11.

Alexiou C, Beggs D, Salama FD et al (1998) Surgery for esophageal cancer in elderly patients: the view from Nottingham. J Thorac Cardiovasc Surg 116(4):545–553PubMedCrossRef

12.

Attwood SE, Lewis CJ, Caplin S et al (2003) Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol 1(4):258–263PubMedCrossRef

13.

Morris CD, Byrne JP, Armstrong GR et al (2001) Prevention of the neoplastic progression of Barrett’s oesophagus by endoscopic argon beam plasma ablation. Br J Surg 88(10):1357–1362PubMedCrossRef

14.

Ell C, May A, Gossner L et al (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology 118(4):670–677PubMedCrossRef

15.

Satodate H, Inoue H, Fukami N et al (2004) Squamous reepithelialization after circumferential endoscopic mucosal resection of superficial carcinoma arising in Barrett’s esophagus. Endoscopy 36(10):909–912PubMedCrossRef

16.

Barr H, Tralau CJ, Boulos PB et al (1987) The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal-injury. Photochem Photobiol 46(5):795–800PubMedCrossRef

17.

Shaheen NJ, Inadomi JM, Overholt BF et al (2004) What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut 53(12):1736–1744PubMedCrossRef

18.

Vij R, Triadafilopoulos G, Owens DK et al (2004) Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc 60(5):739–756PubMedCrossRef

19.

Overholt BF, Lightdale CJ, Wang KK et al (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62(4):488–498PubMedCrossRef

20.

Van Laethem JL, Peny MO, Salmon I et al (2000) Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus. Gut 46(4):574–577PubMedCrossRef

21.

Overholt BF, Panjehpour M, Halberg DL (2003) Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 58(2):183–188PubMedCrossRef

22.

Shand A, Dallal H, Palmer K et al (2001) Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut 48(4):580–581PubMedCrossRef

23.

Regula J, MacRobert AJ, Gorchein A et al (1995) Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX—a pilot study. Gut 36(1):67–75PubMedCrossRef

24.

Kelty CJ, Ackroyd R, Brown NJ et al (2004) Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett’s esophagus. Surg Endosc 18(3):452–458PubMedCrossRef

25.

Pech O, Gossner L, May A et al (2005) Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 62(1):24–30PubMedCrossRef

26.

Gossner L, Stolte M, Sroka R et al (1998) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology 114(3):448–455PubMedCrossRef

27.

Ackroyd R, Kelty CJ, Brown NJ et al (2003) Eradication of dysplastic Barrett’s oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 35(6):496–501PubMedCrossRef

28.

Kelty CJ, Ackroyd R, Brown NJ et al (2004) Endoscopic ablation of Barrett’s oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 20(11–12):1289–1296PubMedCrossRef

29.

Barr H, Shepherd NA, Dix A et al (1996) Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348(9027):584–585PubMedCrossRef

30.

Peters F, Kara M, Rosmolen W et al (2005) Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy 37(5):418–424PubMedCrossRef

31.

Ackroyd R, Brown NJ, Davis MF et al (2000) Photodynamic therapy for dysplastic Barrett’s oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 47(5):612–617PubMedCrossRef

32.

Hage M, Siersema PD, van Dekken H et al (2004) 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial. Gut 53(6):785–790PubMedCrossRef

33.

Forcione DG, Hasan T, Ortel BJ et al (2004) Optimization of aminolevulinic acid-based photodynamic therapy of Barrett’s esophagus with high grade dysplasia. Gastrointest Endosc 59(5):AB251CrossRef

34.

Panjehpour M, Overholt BF, Phan MN et al (2005) Optimization of light dosimetry for photodynamic therapy of Barrett’s esophagus: efficacy vs. incidence of stricture after treatment. Gastrointest Endosc 61(1):13–18PubMedCrossRef

35.

Schlemper RJ, Riddell RH, Kato Y et al (2000) The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47(2):251–255PubMedCrossRef

36.

Lovat LB, Jamieson NF, Novelli MR et al (2005) Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett’s columnar lined esophagus. Gastrointest Endosc 62(4):617–623PubMedCrossRef

37.

van Veen RL, Aalders MC, Pasma KL et al (2002) In situ light dosimetry during photodynamic therapy of Barrett’s esophagus with 5-aminolevulinic acid. Lasers Surg Med 31(5):299–304PubMedCrossRef

38.

Stringer MR, Kelty CJ, Ackroyd, R, Brown SB (2006) Light dosimetry measurements during ALA-PDT of Barrett’s oesophagus. Photodiag Photodynam Ther 3:19–26CrossRef

39.

Tsutsui H, MacRobert AJ, Curnow A et al (2002) Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats. Lasers Med Sci 17(2):101–109PubMedCrossRef

40.

Curnow A, McIlroy BW, Postle-Hacon MJ et al (1999) Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol 69(1):71–76PubMedCrossRef

41.

Haringsma J, Siersema PD, Kuipers EJ (2004) Endoscopic ablation of Barrett’s neoplasia. Rotterdam results. Gastrointest Endosc 59(5):AB252CrossRef

42.

van Hillegersberg R, Haringsma J, ten Kate FJW et al (2003) Invasive carcinoma after endoscopic ablative therapy for high-grade dysplasia in Barrett’s oesophagus. Dig Surg 20(5):440–444PubMedCrossRef

43.

Basu KK, Pick B, Bale R et al (2002) Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut 51(6):776–780PubMedCrossRef

44.

Ban S, Mino M, Nishioka NS et al (2004) Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett’s esophagus. Am J Surg Pathol 28(11):1466–1473PubMedCrossRef

45.

Ackroyd R, Tam W, Schoeman M et al (2004) Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett’s esophagus after antireflux surgery. Gastrointest Endosc 59(1):1–7PubMedCrossRef

46.

Hornick JL, Blount PL, Sanchez CA et al (2005) Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett’s esophagus. Am J Surg Pathol 29(3):372–380PubMedCrossRef

Titel: How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett’s esophagus
verfasst von: Gary D. Mackenzie
Neil F. Jamieson
Marco R. Novelli
C. Alexander Mosse
Benjamin R. Clark
Sally M. Thorpe
Stephen G. Bown
Laurence B. Lovat
Publikationsdatum: 01.04.2008
Verlag: Springer-Verlag
Erschienen in: Lasers in Medical Science / Ausgabe 2/2008
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-007-0473-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett’s esophagus

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Multilaser photoplethysmography technique

Modeling thermotherapy in vocal cords novel laser endoscopic treatment

Micro-shear bond strength of Er:YAG-laser-treated dentin

Effects of laser irradiation on the release of basic fibroblast growth factor (bFGF), insulin like growth factor-1 (IGF-1), and receptor of IGF-1 (IGFBP3) from gingival fibroblasts

Study of visible and mid-infrared laser ablation mechanism of PMMA and intraocular lenses: experimental and theoretical results

Laser-induced thermotherapy for lung tissue—evaluation of two different internally cooled application systems for clinical use